Browsing Tag

ATH1017

Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American…

Jason Junior Mar 3, 2022

Active metabolite of fosgonimeton (ATH-1017) enhances the HGF/MET system, resulting in neurotrophic and procognitive effects In two unique disease models, ATH-1020 reduces depression-like behaviors, and normalizes sensory processing…

Health

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in…

Jason Junior Nov 10, 2021

– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late…

Health

Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on…

Jason Junior Sep 29, 2021

BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today…

Health

Athira Pharma to Present ATH-1017 Phase 1 Translational Data at the Alzheimer’s Association…

Jason Junior Jul 19, 2021

BOTHELL, Wash., July 19, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today…